Pembrolizumab
Low Grade Serous Carcinoma
North Eastern German Society of Gynaecological Oncologymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Low Grade Serous Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Letrozole Gynecologic Oncology Group | Phase 2/3 | BB |
Hycamtin National Cancer Institute (NCI) | Phase 2/3 | B |
Inno-206 National Cancer Institute (NCI) | Phase 2/3 | B |
TAMOXIFEN National Cancer Institute (NCI) | Phase 2/3 | B |
gsk1120212 National Cancer Institute (NCI) | Phase 2/3 | B |
azd6244 National Cancer Institute (NCI) | Phase 2 | B |
Ribociclib Gynecologic Oncology Group | Phase 2 | CCC |
Same molecule, other indications
Pembrolizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →